Cannabidiol vs placebo
Serious adverse events · people with active UC
Cannabidiol showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 0.15 [0.01, 2.83]1 study · 60 participantsLow
Findings
What do systematic reviews say?
537 questions · 558 findings · 32 reviews · Gut
No studies found 134 · 24%GRADE not reported 11 · 2%Very low 143 · 25.6%Low 138 · 24.7%Moderate 106 · 19%High 26 · 4.7%
Cannabidiol vs placebo
Withdrawals due to adverse events · people with active UC
Cannabidiol showed no clear difference in withdrawal due to adverse event compared with placebo (low certainty).
1 finding from 1 review
- RR 2.14 [0.83, 5.51]1 study · 60 participantsLow
Cannabis cigarettes vs placebo
Clinical remission · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Cannabis cigarettes vs placebo
Clinical response · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Bismuth subsalicylate vs placebo
Clinical response · patients with active lymphocytic colitis
It is very uncertain whether bismuth subsalicylate changes clinical response compared with placebo (very low certainty).
1 finding from 1 review
- RR 5.25 [0.94, 1.9]1 study · 5 participantsVery low
Bismuth subsalicylate vs placebo
Histological response · patients with active lymphocytic colitis
It is very uncertain whether bismuth subsalicylate changes histological response compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.33 [0.27, 6.6]1 study · 5 participantsVery low
Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Clinical response · patients with active lymphocytic colitis
Budesonide may leads to higher clinical response compared with mesalazine (low certainty).
1 finding from 1 review
- RR 2.03 [1.25, 3.33]2 studies · 57 participantsLow
Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Histological response · patients with active lymphocytic colitis
Budesonide may leads to higher histological response compared with mesalazine (low certainty).
1 finding from 1 review
- RR 2.44 [1.13, 5.28]2 studies · 39 participantsLow
Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Adverse events · patients with active lymphocytic colitis
Budesonide showed no clear difference in adverse events compared with mesalazine (low certainty).
1 finding from 1 review
- RR 0.67 [0.12, 3.59]1 study · 42 participantsLow
Beclometasone vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Clinical response at 8 weeks · Patients with active or quiescent lymphocytic colitis
Beclometasone dipropionate showed no clear difference in clinical response at 8 weeks compared with mesalazine (low certainty).
1 finding from 1 review
- RR 0.97 [0.75, 1.24]1 study · 46 participantsLow
Beclometasone vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Maintenance of clinical response · Patients with active or quiescent lymphocytic colitis
It is very uncertain whether beclometasone dipropionate changes maintenance of clinical response at 12 weeks compared with mesalazine (very low certainty).
1 finding from 1 review
- RR 1.29 [0.4, 4.18]1 study · 46 participantsVery low
Azathioprine or 6‐mercaptopurine vs placebo
Clinical remission · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical remission compared with placebo (moderate certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.23 [0.97, 1.55]5 studies · 380 participantsModerate
Azathioprine vs infliximab
Adverse events · Patients with active Crohn's disease
Azathioprine showed no clear difference in adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.01 [0.93, 1.08]1 study · 324 participantsModerate
Azathioprine vs infliximab
Withdrawals due to adverse events · Patients with active Crohn's disease
Azathioprine showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.47 [0.96, 2.23]1 study · 324 participantsModerate
Azathioprine vs infliximab
Serious adverse events · Patients with active Crohn's disease
Azathioprine showed no clear difference in serious adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.12 [0.77, 1.62]1 study · 324 participantsModerate
Azathioprine + infliximab vs infliximab
Clinical remission · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to higher clinical remission compared with infliximab (moderate certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.26 [1.03, 1.54]1 study · 338 participantsModerate
Azathioprine + infliximab vs infliximab
Clinical remission off steroids · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to higher clinical remission off steroids compared with infliximab (moderate certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.23 [1.02, 1.47]2 studies · 383 participantsModerate
Azathioprine + infliximab vs infliximab
Mucosal healing · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to higher mucosal healing compared with infliximab (moderate certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.5 [1.02, 2.19]1 study · 210 participantsModerate
Azathioprine + infliximab vs infliximab
Adverse events · Patients with active Crohn's disease
Azathioprine + infliximab showed no clear difference in adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.01 [0.94, 1.09]1 study · 342 participantsModerate
Azathioprine + infliximab vs infliximab
Withdrawals due to adverse events · Patients with active Crohn's disease
Azathioprine + infliximab showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.16 [0.75, 1.8]1 study · 342 participantsModerate